A Study to Evaluate ALN-4324
Phase 1/2
144
about 2.5 years
18–75
7 sites in CA, DC, FL +3
About this study
This trial is testing a treatment called ALN-4324 in two groups of people. One group includes healthy overweight or obese volunteers, and the other group includes adults with type 2 diabetes (T2DM). The goal is to see if this treatment is safe and how it works in both groups.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ALN-4324
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Frequency of Adverse Events (AEs), Part B: Frequency of Adverse Events
Secondary: Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-4324 in Plasma, Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-4324 in Plasma, Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-4324 in Plasma, Part B: Change from Baseline in HbA1c